ESPR vs NEM · rev $332.3M vs P/E 14, rev $13.43B
Esperion Therapeutics Inc (ESPR) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
ESPR currently screens at market cap $816.9M. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the ESPR and NEM stock pages for the full models.
Not investment advice.